| ● | Our ability to continue our relationship with the University of Texas MD Anderson Cancer Center (MD Anderson), including, but not limited to, our ability to maintain current licenses and license future intellectual property resulting from our sponsored research agreements with MD Anderson; |
| ● | The success or the lack thereof, including the ability to recruit subjects and onboard new clinical trial sites on a timely basis, for a variety of reasons, of our clinical trials through all phases of clinical development; |
| ● | Our ability to satisfy any requirements imposed by the United States (US) Food & Drug Administration (FDA) (or its foreign equivalents) as a condition of our clinical trials proceeding or beginning as planned; |
| ● | World-wide events including geopolitical conflicts, public health emergencies, and global supply chain disruptions that may affect our clinical trials, clinical drug candidate supplies, preclinical activities and our ability to raise future financing; |
| ● | Our ability to obtain additional funding on a timely basis to commence or continue our clinical trials, fund operations and develop our product candidates; |
| ● | The need to obtain and retain regulatory approval of our drug candidates, both in the United States and in Europe, and in countries deemed necessary for future trials; |
| ● | Our ability to complete our clinical trials in a timely fashion in line with our stated milestones and within our expected budget and resources; |
| ● | Our ability to maintain compliance with the continued listing requirements of the Nasdaq Capital Market; |
| ● | Our ability to source our drug products at reasonable prices; |
| ● | Any delays in regulatory review and approval of drug candidates in clinical development; |
| ● | Potential efficacy of our drug candidates; |
| ● | Our ability to commercialize our drug candidates; |
| ● | Market acceptance of our drug candidates; |
| ● | Competition from existing therapies or new therapies that may emerge; |
| ● | Potential product liability claims; |
| ● | Our dependency on third-party manufacturers to successfully, and timely, supply or manufacture our drug candidates for our preclinical work and our clinical trials; |
| ● | Our ability to adequately support future growth; and |
You should also consider carefully the statements under “Risk Factors” and other sections of this prospectus, and the documents we incorporate by reference, which address additional facts that could cause our actual results to differ from those set forth in the forward-looking statements. We caution investors not to place significant reliance on the forward-looking statements contained in this prospectus, and the documents we incorporate by reference. We undertake no obligation to publicly update or review any forward-looking statements, whether as a result of new information, future developments or otherwise.
